Marksans Pharma Delivers Robust Q2FY27 Growth Driven by Core Markets
Marksans Pharma Ltd · Investor Presentation · 04 Nov 2026, 7:10 pm
Marksans Pharma Delivers Robust Q2FY27 Growth Driven by Core Markets Marksans Pharma posted strong Q2FY27 operating revenue of ₹940.2 cr, up 30.5% YoY (25% organic), supported by 64.9% growth in UK & Europe and solid US traction. EBITDA rose 48.3% YoY to ₹214.3 cr, with margins expanding 274 bps to 22.8% on operating leverage, while PAT reached ₹143.5 cr (+44.8% YoY). H1FY27 operating cash flow surged 4.3x to ₹322 cr, leaving a net cash balance of ₹1,095 cr as of 30th Sep'26. TTM ROCE improved significantly to 24.7%.
Original exchange filing (PDF)
More announcements from Marksans Pharma Ltd
- Transcript of Investors/Analyst meet on Q2 FY27 Financial Results · 13 Nov 2026
- Audio Recording of investor(s)/analyst(s) meet Conference Call on Q2 FY 27 Financial Results · 05 Nov 2026
- Allotment of Equity Shares under Marksans Employees Stock Option Scheme 2024 · 04 Nov 2026
- Press Release for Financial Results Q2FY27 · 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30 September 2026 · 04 Nov 2026
- Marksans Pharma Limited has submitted to the Exchange, unaudited financial results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
- Please find attached outcome of the Board meeting held on 04 November 2026 · 04 Nov 2026
- Intimation of schedule for Q2FY27 Earnings Conference Call · 05 Nov 2026
